• Research/Demonstration Projects: Kenya has been the site of trials and demonstration projects of daily oral PrEP in serodiscordant couples, heterosexual women, men who have sex with men and sex workers. PrEP is slated to be included in the PEPFAR-supported DREAMS initiative focused on young women and adolescent girls. Click here for a full list of planned, ongoing and completed research/demonstration projects.
  • Drug Registration: Kenya’s Pharmacy and Poisons Board (PPB)—the regulatory body that considers new drugs—approved Truvada TDF/FTC for PrEP for adults at high risk of sexually acquiring HIV-1 infection.
  • Policy/Regulatory: In May 2017, Kenya launched a national PrEP program making PrEP available for people at substantial, ongoing risk of HIV infection. The National AIDS & STI Control Program (NASCOP) published the “PrEP Implementation Framework” to provide guidance on the rollout of PrEP in Kenya. Additionally, PrEP is incorporated into the Kenyan HIV Prevention Revolution Roadmap and is also identified as an evidence-based intervention in the most recent Kenya National Strategic Framework (KASF). PrEP is also included in the Guidelines on use of ARV drugs for treating and preventing HIV infections in Kenya – 2016 edition.
  • Advocacy: Civil society and Kenyan researchers have worked in close collaboration to advance PrEP access in country, with dialogues and advocacy among key populations and at the national stakeholder level.
  • Country Close-Up: For a more detailed look at the landscape in Kenya, click here.

News Spotlight